You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
Temozolomide in low-grade gliomas: living longer and better
  1. Jeremy Rees
  1. Correspondence to Dr Jeremy Rees, National Hospital for Neurology and Neurosurgery, Queen Square, Mailbox 99, London WC1N 3BG, UK; Jeremy.rees{at}ucl.ac.uk

http://dx.doi.org/10.1136/jnnp-2014-308880

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Low-grade gliomas (LGGs) account for about a third of gliomas overall and 15% of all primary brain tumours. In adults, the majority of LGGs are WHO Grade II astrocytomas and oligodendrogliomas, which differ in molecular fingerprints and median survival, but share a propensity to malignant transformation after a number of years. Up to 90% of LGGs present with seizures and epilepsy may be the only symptom for many years, significantly impairing quality of life and impacting on social and professional functioning.1 In about 50% of cases, the epilepsy is refractory to antiepileptic drugs (AEDs) with a quarter of patients requiring 3 or more AEDs.2 Koekkoek et al3 report on the effect of temozolomide (TMZ), an oral alkylating chemotherapy agent, on seizures in LGG, and surprisingly find a positive impact on prognosis in those patients deriving significant seizure reduction.

    Owing to the large variability in prognosis and the …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles